Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
107M
-
Number of holders
-
108
-
Total 13F shares, excl. options
-
65.8M
-
Shares change
-
-2.33M
-
Total reported value, excl. options
-
$325M
-
Value change
-
-$12M
-
Put/Call ratio
-
0.9
-
Number of buys
-
66
-
Number of sells
-
-30
-
Price
-
$4.95
Significant Holders of MAXCYTE, INC. - Common Stock, par value $0.01 per share (MXCT) as of Q1 2023
115 filings reported holding MXCT - MAXCYTE, INC. - Common Stock, par value $0.01 per share as of Q1 2023.
MAXCYTE, INC. - Common Stock, par value $0.01 per share (MXCT) has 108 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65.8M shares
of 107M outstanding shares and own 61.58% of the company stock.
Largest 10 shareholders include BlackRock Inc. (7.02M shares), Vitruvian Partners LLP (5.04M shares), Casdin Capital, LLC (4.93M shares), VANGUARD GROUP INC (4.89M shares), Blue Water Life Science Advisors, LP (3.23M shares), MILLENNIUM MANAGEMENT LLC (2.85M shares), Stonepine Capital Management, LLC (2.71M shares), ArrowMark Colorado Holdings LLC (2.3M shares), Holocene Advisors, LP (2.12M shares), and BAMCO INC /NY/ (1.99M shares).
This table shows the top 108 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.